---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127184"
form_type: "8-K"
ticker: null
cik: "0001260990"
company_name: "Oncternal Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:17:33.809313+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Oncternal Therapeutics cuts remaining workforce; retains 4 part-time employees for strategic alternatives

## Summary
- Workforce reduction of all remaining employees effective Dec 2, 2024; only 4 retained part-time.
- Estimated severance and termination costs of ~$2.4M, primarily recognized in Q4 2024.
- CEO James B. Breitmeyer and officer Richard G. Vincent transition to 50% part-time effective Dec 2.
- Board unanimously approved reduction on Nov 13; company exploring strategic alternatives, including sale or dissolution.

## SEC filing metadata
- accession: 0000950170-24-127184
- form_type: 8-K
- cik: 0001260990
- company_name: Oncternal Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/onct-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127184
- JSON: https://secwatch.observer/filing/0000950170-24-127184.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127184.txt

## Key facts
- Executive change
  Richard G. Vincent changed role as other_named_officer at Oncternal Therapeutics, Inc..
  - Action: transitioned to part-time employment status
  source text: In connection with the workforce reduction, James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent will transition to part-time employment status, reducing their time commitment to 50% of their current duties effective December 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm
- Executive change
  James B. Breitmeyer changed role as Chief Executive Officer at Oncternal Therapeutics, Inc..
  - Action: transitioned to part-time employment status
  - Role: Chief Executive Officer
  source text: In connection with the workforce reduction, James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent will transition to part-time employment status, reducing their time commitment to 50% of their current duties effective December 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm
- Restructurings & Charges
  Oncternal Therapeutics, Inc. announced a restructuring with charges of approximately $2.4 million (workforce reduction of its remaining employees).
  - Type: restructuring
  - Charge: approximately $2.4 million
  - Headcount: workforce reduction of its remaining employees
  source text: Oncternal currently estimates that it will incur charges associated with the workforce reduction of all of its remaining employees of approximately $2.4 million primarily related to employee severance payments, benefits and related termination costs
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024127184/0000950170-24-127184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.